Company Overview

We See Every Day as an Opportunity to Disrupt Conventional Thinking

Because we are a purpose-driven company that moves people to realize their best selves through improved vision.

Our Story

Delivering Solutions to Reshape Vision Possibilities

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities. Orasis has developed Qlosi® (pilocarpine HCl ophthalmic solution) 0.4%, a novel corrective eye drop for the treatment of presbyopia, or age-related blurry near vision, in adults.

With deep expertise in eye care, and a willingness to take on challenges, we are committed to transforming the standard of care for near vision correction, with an initial focus on presbyopia, or age-related blurry near vision.

Orasis Pharmaceuticals headquarters lobby

Presbyopia is the gradual loss of your eye’s ability to focus on near objects as a result of the natural aging process, which occurs mostly after the age of 40, and affects almost two billion people globally.

Orasis is led by a collaborative team of industry executives and eye care professionals, whose expertise guides our business, people and principles to make a meaningful difference in the eyecare community.

Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors including Arboretum Ventures, Johnson & Johnson Innovation – JJDC, Inc., Catalio Capital Management, Visionary Ventures, Bluestem Capital, SBI (Japan) Innovation Fund, Sequoia Capital, LifeSci Venture Partners, Maverick Ventures Israel and other private investors.

Orasis has offices in the U.S. and Israel.

Get in Touch

Ready to see what's possible? Contact us here.

Contact Us